Weight-loss drug adoption is reshaping aesthetic demand; practices are retooling service mix to capture body contouring and skin tightening volume.
A wave of GLP-1 agonist adoption—driven by Ozempic, Wegovy, Mounjaro, and their generics—is creating a multi-billion-dollar aesthetic opportunity that practices are racing to capture. The mechanism is straightforward: rapid weight loss from GLP-1 use leaves loose skin, deflated cheeks, and loss of facial volume. Patients want correction, and they want it fast.
Practices are responding by expanding body contouring (RF microneedling, radiofrequency, ultrasound), facial volumization (fillers, biostimulators), and skin-tightening modalities. Inmode's Morpheus8 and Cutera's Xeo are seeing uptick in body-contouring bookings. Filler consumption is rising among GLP-1 users seeking cheek and temple restoration. Some practices are bundling services—weight-loss support counseling paired with aesthetic procedures—to capture the full patient lifecycle.
GLP-1 adoption is driving multi-billion-dollar aesthetic opportunity in body contouring and facial volumization.
The economics are favorable. GLP-1 patients are often affluent, motivated, and willing to invest in results. But the window is time-limited; practices that don't position now will lose first-mover advantage as competitors build expertise and patient pipelines.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
